Health09/23/2026@HealthDesk
Retatrutide Delivers 28.3% Weight Loss in Lilly's TRIUMPH-1 Phase 3 Trial
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
Starts 05/21/2026CONFIRMED 87% CONFIDENCE125 days agoLilly's release is datelined "INDIANAPOLIS, May 21, 2026" and says the company "today announced positive topline results from TRIUMPH-1".^[1]
People on the top 12 mg dose of Lilly's triple-hormone shot retatrutide lost an average of 28.3% of their body weight (70.3 lbs) over 80 weeks, and 30.3% by two years in the extension - weight loss at the level of bariatric surgery.
0.69
Health09/23/2026@HealthDesk
Lilly Agrees to Acquire Merida Biosciences for Up to $2.875 Billion
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
Starts 08/31/2026CONFIRMED 88% CONFIDENCE23 days agoThe release is datelined "INDIANAPOLIS and CAMBRIDGE, Mass., Aug. 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Merida".^[1]
Lilly agrees to buy Merida Biosciences, whose Phase 1 MER511 is built to destroy the autoantibodies behind Graves' disease and thyroid eye disease, for up to $2.875 billion in cash.
$2.9B
0.66
Health09/20/2026@TechDesk
Lilly's Foundayo (Orforglipron) Weight-Loss Pill Approved by FDA
Eli Lilly…Indianapolis, Indiana
Starts 04/01/2026CONFIRMED 85% CONFIDENCE175 days agoLilly^[3] and the FDA^[4] approval letter date the approval April 1, 2026.
The FDA approved Eli Lilly's Foundayo, a once-daily GLP-1 pill for weight loss that needs no food or water restrictions, with direct-to-consumer sales from April 6.
0.66
Health09/23/2026@HealthDesk
Lilly Agrees to Acquire Centessa for Up to $7.8 Billion
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
Starts 03/31/2026CONFIRMED 87% CONFIDENCE176 days agoThe joint release is datelined "INDIANAPOLIS and BOSTON and LONDON, March 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Centessa".^[1]
Lilly agrees to buy Centessa Pharmaceuticals, maker of the orexin agonist cleminorexton for narcolepsy, for $38 a share in cash (about $6.3 billion) plus a CVR worth up to $1.5 billion more; the deal closed on 24 June 2026.
$7.8B
0.65
Health09/23/2026@HealthDesk
Lilly Agrees to Buy Three Vaccine Developers for Up to $3.83 Billion
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
Starts 05/26/2026CONFIRMED 87% CONFIDENCE120 days agoLilly's release is datelined "INDIANAPOLIS, May 26, 2026" and says Lilly "today announced agreements to acquire three companies".^[1]
Lilly moves into infectious disease by agreeing to buy Curevo (shingles), LimmaTech Biologics (staph and other bacteria) and Vaccine Company (Epstein-Barr virus) for up to $3.83 billion combined in cash.
$3.8B
0.64
Health09/23/2026@HealthDesk
FDA Approves Lilly's Inluriyo With Verzenio for ESR1-Mutated Breast Cancer
Eli Lilly…Bowditch Road, Federal Research Center, Hillandale, Montgomery County, Maryland, 20993, United States
Starts 09/18/2026CONFIRMED 85% CONFIDENCE5 days agoLilly's release is datelined "INDIANAPOLIS, Sept. 18, 2026" and says it "announced today that the U.S. Food and Drug Administration (FDA^[4]) has granted full approval"; the FDA's own notice gives the approval date as September 18, 2026.
An all-oral pairing that doubled median progression-free survival to 11.1 months from 5.5 in ESR1-mutated patients in the EMBER-3 trial. It is Inluriyo's second FDA approval in under a year.
0.63
Health09/23/2026@HealthDesk
FDA Approves Abbott's TactiFlex Duo Ablation Catheter
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
Starts 09/08/2026CONFIRMED 86% CONFIDENCE15 days agoThe release is datelined "ABBOTT PARK, Ill., Sept. 8, 2026" and says Abbott "announced today it has received U.S. Food and Drug Administration (FDA^[3]) approval" (the FDA's record gives a decision date of 09/04/2026).
The FDA approved Abbott's TactiFlex Duo, a catheter that can deliver pulsed field ablation, radiofrequency energy or both in one procedure to treat complex atrial fibrillation. The approval rested on the FlexPulse IDE study.
0.63
Health09/23/2026@HealthDesk
FDA Approves Abbott's Volt PFA System for AFib
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
Starts 12/22/2025CONFIRMED 84% CONFIDENCE275 days agoThe release is datelined "ABBOTT PARK, Ill., Dec. 22, 2025" and says Abbott "today announced" the FDA^[5] has approved the Volt PFA System (the FDA's own record gives a decision date of 12/19/2025).
The FDA approved Abbott's Volt pulsed field ablation system, a balloon-in-basket catheter that maps, paces and ablates, to treat paroxysmal and persistent atrial fibrillation. The approval rested on the 392-patient VOLT-AF IDE study at 40 centers.
0.62
Health09/23/2026@HealthDesk
J&J Signs a Drug-Pricing Deal With Trump and Joins TrumpRx
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United StatesJohnson & Johnson…
Starts 01/08/2026CONFIRMED 86% CONFIDENCE258 days agoJ&J's release is datelined "New Brunswick, N.J. – JANUARY 8, 2026" and says the company "today announced a voluntary agreement with the Trump Administration"; coverage followed on 9 January.^[1]
Johnson & Johnson signed a voluntary most-favored-nation drug-pricing agreement with the Trump administration, selling medicines through TrumpRx.gov and to Medicaid at prices comparable to other developed countries in exchange for an exemption from pharmaceutical tariffs, and announced two new US plants in Pennsylvania and North Carolina.
0.62
Health09/23/2026@HealthDesk
Lilly Presents eloraTZP Phase 2 Results at EASD 2026 in Milan
Allianz MiCo, Via Demetrio Stratos, Bolla, Milan, Lombardy 20149, ItalyEli Lilly…
Starts 09/30/2026 2:30PMSCHEDULED 86% CONFIDENCEin 7 daysLilly's release lists "EloraTZP symposium | Wednesday, September 30, 2026 | 4:30 to 5:30 p.m. CEST", and the EASD^[2] 2026 Final Programme puts the session at 16:30 - 17:30 on Wednesday 30 September in Budapest Hall.
First Phase 2 results for eloraTZP - Lilly's once-weekly amylin drug eloralintide combined with tirzepatide (Mounjaro, Zepbound) - in adults with obesity or overweight and type 2 diabetes, unveiled at an EASD symposium on amylin in Milan.
0.61
Health09/23/2026@HealthDesk
Eli Lilly Q3 2026 Earnings Call
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
Starts 10/29/2026 2:00PMESTIMATED 71% CONFIDENCEin 36 daysLilly has not confirmed the date yet (no "Lilly confirms date and conference call for third-quarter 2026" release as of 22 Sep 2026; the Q2 one came out on 22 July for 5 August). Public.com^[2] and Nasdaq^[3] list the Q3 report as "expected" on 10/29/2026 "before market open", matching Lilly's pattern (Q3 2025 reported October 30, 2025) and its calls, which "will begin at 10 a.m. Eastern time" - so 29 Oct 2026, 10:00 ET (14:00 UTC), estimated until Lilly's confirmation release.
Eli Lilly is expected to report third-quarter 2026 results on 29 October, with its usual 10 a.m. ET conference call. It goes in guiding to $85-87 billion of 2026 revenue after second-quarter revenue jumped 48% to $23.0 billion on Mounjaro and Zepbound.
0.61
Health09/23/2026@HealthDesk
Abbott Settles DOJ Infant Formula Claims for $385 Million
Abbott Laboratories…Sturgis, Saint Joseph County, Michigan, 49091, United States
Starts 09/14/2026CONFIRMED 88% CONFIDENCE9 days agoThe release is datelined "ABBOTT PARK, Ill., Sept. 14, 2026" and says Abbott "has reached an agreement"; the DOJ release is dated Monday, September 14, 2026.^[1]
Abbott will pay about $385 million ($384,999,040) to resolve Justice Department, state and whistleblower claims over powdered infant formula made at its Sturgis, Michigan, plant, the site of the 2022 recall. Abbott admits no liability, and the government has closed its criminal investigation.
$385M
0.61

3 months late

Lilly "plans to subsequently submit retatrutide in Q1 2027 for U.S. approval" - no day is given, so the pin takes the last day of the first quarter of 2027.^[1]

First promised for 12/31/2026; now 3 months later. Stated: Lilly had listed retatrutide among medicines that might be submitted by the end of 2026 (BioPharma Dive; BioSpace: "Previously a filing was expected later this year"); on 23 July 2026 it moved the U.S. filing to Q1 2027 to finish the manufacturing and quality-control (CMC) data - about one quarter later.

Start: Mar 31, 202750% CONFIDENCEfrom the source

Lilly Submits Retatrutide to the FDA for Approval

Lilly plans to file its Biologics License Application for retatrutide, the triple-hormone obesity shot that cut weight by up to 28.3% in Phase 3, with the FDA in the first quarter of 2027, once its manufacturing data package is complete.

Lilly said on 23 July 2026 that it is completing the Chemistry, Manufacturing, and Controls (CMC) data package required for a Biologics License Application and "plans to subsequently submit retatrutide in Q1 2027 for U.S. approval"^[1]
Its second-quarter results on 5 August repeated the plan: the clinical data package is complete to support global registrations for obesity, obstructive sleep apnea and knee osteoarthritis pain, "with plans to submit a Biologics License Application to the U.S. FDA in the first quarter of 2027"^[2]
The filing had earlier been expected later in 2026^[4]; Lilly told CNBC it needed more time to gather manufacturing and quality-control data for the agency^[3]
The package rests on five positive Phase 3 studies^[1]; in the last two, TRIUMPH-2 patients with type 2 diabetes lost 12.7%, 19.1% and 20.8% of their weight on 4, 9 and 12 mg (up to 49.6 lbs) with A1C down by up to 1.6% at 80 weeks, and TRIUMPH-3 patients with severe obesity and heart disease lost up to 22.6% (55.8 lbs)^[1]
Heart outcomes were less clear-cut: TRIUMPH-3 saw 44 MACE-5 events on retatrutide against 52 on placebo (hazard ratio 0.82), but 27 MACE-3 events against 23 (hazard ratio 1.12)^[1][3]
"We now have the clinical data package to support global submissions for retatrutide," said Kenneth Custer, president of Lilly Cardiometabolic Health^[1]

@HealthDesk

References 477% CONFIDENCE

The first entry is always the pin's source. Overall confidence is a weighted average of how firmly each reference supports the start and end times used above; a reference counts half as much for every 180 days older than the newest.

[1]50%
prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-successful-in-two-additional-phase-3-obesity-trials-delivering-significant-improvements-in-weight-and-a1c-302832674.html
prnewswire.com· Posted Sep 23, 2026· Starts Mar 31, 2027 ✓· 29% of score
Lilly "plans to subsequently submit retatrutide in Q1 2027 for U.S. approval" - no day is given, so the pin takes the last day of the first quarter of 2027.
[2]92%
Lilly reports second-quarter 2026 financial results (Form 8-K Exhibit 99.1)
sec.gov· Published Aug 5, 2026· 24% of score
Lilly's Q2 2026 earnings release filed with the SEC on 5 August 2026: the retatrutide clinical data package is complete to support global registrations for obesity, obstructive sleep apnea and knee osteoarthritis pain, "with plans to submit a Biologics License Application to the U.S. FDA in the first quarter of 2027".
[3]88%
Lilly, with new data, to seek FDA approval of obesity drug retatrutide
biopharmadive.com· Published Jul 23, 2026· 23% of score
BioPharma Dive, 23 July 2026: Lilly earlier included retatrutide among medicines that might be submitted by the end of 2026 but now says it is set for an FDA application in the first quarter of next year; Lilly told CNBC it needed more time to gather manufacturing and quality-control data; TRIUMPH-3 MACE-3 27 vs 23.
[4]85%
Lilly preps FDA run for 'triple-G' weight loss drug with Phase 3 data
biospace.com· Published Jul 23, 2026· 23% of score
BioSpace (Tristan Manalac), 23 July 2026: with weight loss topping 20% at 80 weeks in TRIUMPH-2 and TRIUMPH-3, Lilly plans to file for retatrutide's approval in the first quarter of 2027; "Previously a filing was expected later this year."

Suggest a correction

Something missing or wrong? Say it in your own words: a link that backs this pin up, a different start or end date and why, or a fact it lacks or gets wrong. The AI checks it against this pin's sources, searches for better ones, and adds any page that backs you up. The pin's own sources still count most.

Comments

Thread

Respond to this Pin

Health09/23/2026@HealthDesk
Retatrutide Delivers 28.3% Weight Loss in Lilly's TRIUMPH-1 Phase 3 Trial
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
Starts 05/21/2026CONFIRMED 87% CONFIDENCE125 days agoLilly's release is datelined "INDIANAPOLIS, May 21, 2026" and says the company "today announced positive topline results from TRIUMPH-1".^[1]
People on the top 12 mg dose of Lilly's triple-hormone shot retatrutide lost an average of 28.3% of their body weight (70.3 lbs) over 80 weeks, and 30.3% by two years in the extension - weight loss at the level of bariatric surgery.
0.69
Health09/23/2026@HealthDesk
Lilly Agrees to Acquire Merida Biosciences for Up to $2.875 Billion
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
Starts 08/31/2026CONFIRMED 88% CONFIDENCE23 days agoThe release is datelined "INDIANAPOLIS and CAMBRIDGE, Mass., Aug. 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Merida".^[1]
Lilly agrees to buy Merida Biosciences, whose Phase 1 MER511 is built to destroy the autoantibodies behind Graves' disease and thyroid eye disease, for up to $2.875 billion in cash.
$2.9B
0.66
Health09/20/2026@TechDesk
Lilly's Foundayo (Orforglipron) Weight-Loss Pill Approved by FDA
Eli Lilly…Indianapolis, Indiana
Starts 04/01/2026CONFIRMED 85% CONFIDENCE175 days agoLilly^[3] and the FDA^[4] approval letter date the approval April 1, 2026.
The FDA approved Eli Lilly's Foundayo, a once-daily GLP-1 pill for weight loss that needs no food or water restrictions, with direct-to-consumer sales from April 6.
0.66
Health09/23/2026@HealthDesk
Lilly Agrees to Acquire Centessa for Up to $7.8 Billion
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
Starts 03/31/2026CONFIRMED 87% CONFIDENCE176 days agoThe joint release is datelined "INDIANAPOLIS and BOSTON and LONDON, March 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Centessa".^[1]
Lilly agrees to buy Centessa Pharmaceuticals, maker of the orexin agonist cleminorexton for narcolepsy, for $38 a share in cash (about $6.3 billion) plus a CVR worth up to $1.5 billion more; the deal closed on 24 June 2026.
$7.8B
0.65
Health09/23/2026@HealthDesk
Lilly Agrees to Buy Three Vaccine Developers for Up to $3.83 Billion
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
Starts 05/26/2026CONFIRMED 87% CONFIDENCE120 days agoLilly's release is datelined "INDIANAPOLIS, May 26, 2026" and says Lilly "today announced agreements to acquire three companies".^[1]
Lilly moves into infectious disease by agreeing to buy Curevo (shingles), LimmaTech Biologics (staph and other bacteria) and Vaccine Company (Epstein-Barr virus) for up to $3.83 billion combined in cash.
$3.8B
0.64
Health09/23/2026@HealthDesk
FDA Approves Lilly's Inluriyo With Verzenio for ESR1-Mutated Breast Cancer
Eli Lilly…Bowditch Road, Federal Research Center, Hillandale, Montgomery County, Maryland, 20993, United States
Starts 09/18/2026CONFIRMED 85% CONFIDENCE5 days agoLilly's release is datelined "INDIANAPOLIS, Sept. 18, 2026" and says it "announced today that the U.S. Food and Drug Administration (FDA^[4]) has granted full approval"; the FDA's own notice gives the approval date as September 18, 2026.
An all-oral pairing that doubled median progression-free survival to 11.1 months from 5.5 in ESR1-mutated patients in the EMBER-3 trial. It is Inluriyo's second FDA approval in under a year.
0.63
Health09/23/2026@HealthDesk
FDA Approves Abbott's TactiFlex Duo Ablation Catheter
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
Starts 09/08/2026CONFIRMED 86% CONFIDENCE15 days agoThe release is datelined "ABBOTT PARK, Ill., Sept. 8, 2026" and says Abbott "announced today it has received U.S. Food and Drug Administration (FDA^[3]) approval" (the FDA's record gives a decision date of 09/04/2026).
The FDA approved Abbott's TactiFlex Duo, a catheter that can deliver pulsed field ablation, radiofrequency energy or both in one procedure to treat complex atrial fibrillation. The approval rested on the FlexPulse IDE study.
0.63
Health09/23/2026@HealthDesk
FDA Approves Abbott's Volt PFA System for AFib
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
Starts 12/22/2025CONFIRMED 84% CONFIDENCE275 days agoThe release is datelined "ABBOTT PARK, Ill., Dec. 22, 2025" and says Abbott "today announced" the FDA^[5] has approved the Volt PFA System (the FDA's own record gives a decision date of 12/19/2025).
The FDA approved Abbott's Volt pulsed field ablation system, a balloon-in-basket catheter that maps, paces and ablates, to treat paroxysmal and persistent atrial fibrillation. The approval rested on the 392-patient VOLT-AF IDE study at 40 centers.
0.62
Health09/23/2026@HealthDesk
J&J Signs a Drug-Pricing Deal With Trump and Joins TrumpRx
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United StatesJohnson & Johnson…
Starts 01/08/2026CONFIRMED 86% CONFIDENCE258 days agoJ&J's release is datelined "New Brunswick, N.J. – JANUARY 8, 2026" and says the company "today announced a voluntary agreement with the Trump Administration"; coverage followed on 9 January.^[1]
Johnson & Johnson signed a voluntary most-favored-nation drug-pricing agreement with the Trump administration, selling medicines through TrumpRx.gov and to Medicaid at prices comparable to other developed countries in exchange for an exemption from pharmaceutical tariffs, and announced two new US plants in Pennsylvania and North Carolina.
0.62
Health09/23/2026@HealthDesk
Lilly Presents eloraTZP Phase 2 Results at EASD 2026 in Milan
Allianz MiCo, Via Demetrio Stratos, Bolla, Milan, Lombardy 20149, ItalyEli Lilly…
Starts 09/30/2026 2:30PMSCHEDULED 86% CONFIDENCEin 7 daysLilly's release lists "EloraTZP symposium | Wednesday, September 30, 2026 | 4:30 to 5:30 p.m. CEST", and the EASD^[2] 2026 Final Programme puts the session at 16:30 - 17:30 on Wednesday 30 September in Budapest Hall.
First Phase 2 results for eloraTZP - Lilly's once-weekly amylin drug eloralintide combined with tirzepatide (Mounjaro, Zepbound) - in adults with obesity or overweight and type 2 diabetes, unveiled at an EASD symposium on amylin in Milan.
0.61
Health09/23/2026@HealthDesk
Eli Lilly Q3 2026 Earnings Call
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
Starts 10/29/2026 2:00PMESTIMATED 71% CONFIDENCEin 36 daysLilly has not confirmed the date yet (no "Lilly confirms date and conference call for third-quarter 2026" release as of 22 Sep 2026; the Q2 one came out on 22 July for 5 August). Public.com^[2] and Nasdaq^[3] list the Q3 report as "expected" on 10/29/2026 "before market open", matching Lilly's pattern (Q3 2025 reported October 30, 2025) and its calls, which "will begin at 10 a.m. Eastern time" - so 29 Oct 2026, 10:00 ET (14:00 UTC), estimated until Lilly's confirmation release.
Eli Lilly is expected to report third-quarter 2026 results on 29 October, with its usual 10 a.m. ET conference call. It goes in guiding to $85-87 billion of 2026 revenue after second-quarter revenue jumped 48% to $23.0 billion on Mounjaro and Zepbound.
0.61
Health09/23/2026@HealthDesk
Abbott Settles DOJ Infant Formula Claims for $385 Million
Abbott Laboratories…Sturgis, Saint Joseph County, Michigan, 49091, United States
Starts 09/14/2026CONFIRMED 88% CONFIDENCE9 days agoThe release is datelined "ABBOTT PARK, Ill., Sept. 14, 2026" and says Abbott "has reached an agreement"; the DOJ release is dated Monday, September 14, 2026.^[1]
Abbott will pay about $385 million ($384,999,040) to resolve Justice Department, state and whistleblower claims over powdered infant formula made at its Sturgis, Michigan, plant, the site of the 2022 recall. Abbott admits no liability, and the government has closed its criminal investigation.
$385M
0.61

More like this

References 477% CONFIDENCE

Suggest a correction

Comments

Thread

More like this